What do we measure when we measure cell-associated HIV RNA

Diagnostic and therapeutic challenges for dermatologists: What shall we do when we don’t know what to do?

What shall we do when we have done everything we could for the diagnosis and treatment of a patient, but were not successful? What shall we do when there is no definite treatment for a patient? What shall we do when we have no diagnosis or treatment for a patient? Some useful suggestions are presented here to get rid of these situations.

Superior Capsule Reconstruction: What Do We Know?

The management of irreparable rotator cuff tears remains challenging. Since its introduction by Mihata in 2012, superiorcapsule reconstruction (SCR) has grown in popularity at an astonishingly rapid rate. The aim of this article is to providea comprehensive review of the available literature, in order to highlight what has so far been published on SCR,covering all aspects including biomechanica...

Examining the developing bone: What do we measure and how do we do it?

The clinical tools available to evaluate bone development in children are often ambiguous, and difficult to interpret. Unfortunately bone densitometry methods (i.e., dual energy X-ray absorptiometry, DXA) which have a relatively straightforward application in adult osteoporosis, are far more difficult to evaluate in the growing skeleton. Even with adequate "adjustment" for bone size or maturity...

How Do We Measure Comorbidity?

This chapter reviews methods used to measure comorbidity in the context of cancer; summarising methods, identifying contexts in which they have been used and assessing the validity, reliability and feasibility of each approach. Measures of comorbidity are categorised according to whether they are based on individual conditions or simple counts, on dysfunction/function of organ systems, on condi...

How do we measure quality?